Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SCYNEXIS, Inc. (SCYX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3000+0.1800 (+8.49%)
At close: 04:00PM EST
2.3900 +0.09 (+3.91%)
After hours: 07:10PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.1200
Open2.1300
Bid2.2800 x 800
Ask2.3900 x 800
Day's Range2.1300 - 2.3100
52 Week Range1.7000 - 7.5800
Volume130,809
Avg. Volume121,719
Market Cap75.111M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.2040
Earnings DateNov 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SCYX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SCYNEXIS, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement